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Abstract: Mithramycin (MTM), a natural product of soil bacteria from the Streptomyces 
genus, displays potent anticancer activity but has been limited clinically by severe side effects 
and toxicities. Engineering of the MTM biosynthetic pathway has produced the 3-side-chain-
modified analogs MTM SK (SK) and MTM SDK (SDK), which have exhibited increased 
anticancer activity and improved therapeutic index. However, these analogs still suffer from 
low bioavailability, short plasma retention time, and low tumor accumulation. In an effort to aid 
with these shortcomings, two nanoparticulate formulations, poly(ethylene glycol)-poly(aspartate 
hydrazide) self-assembled and cross-linked micelles, were investigated with regard to the 
ability to load and pH dependently release the drugs. Micelles were successfully formed with 
both nanoparticulate formulations of each drug analog, with an average size of 8.36 ± 3.21 and 
12.19 ± 2.77 nm for the SK and SDK micelles and 29.56 ± 4.67 nm and 30.48 ± 7.00 nm for 
the SK and SDK cross-linked micelles respectively. All of the drug-loaded formulations showed 
a pH-dependent release of the drugs, which was accelerated as pH decreased from 7.4 to 5.0. 
The micelles retained biological activity of SK and SDK entrapped in the micelles, suppressing 
human A549 lung cancer cells effectively.
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Introduction
Mithramycin (MTM), an aureolic acid-type polyketide antibiotic produced naturally by 
soil bacteria from the Streptomyces genus, exhibits anticancer activity by cross-linking 
GC-rich DNA and shutting down proto-oncogenes, particularly those triggered by Sp 
(specificity protein) transcription factors, eg, Sp1 and Sp3.1–5 Overexpression of Sp1 
has been observed in several cancers and has been linked to the control of cell growth, 
survival, and differentiation, all of which are important in cancer progression.6–8 MTM 
has been used clinically in the past to treat testicular cancer, Paget’s bone disease, and 
hypercalcemia but has been severely limited by its poor bioavailability and toxic side 
effects such as hepatic, gastrointestinal, bone marrow, and renal toxicities.9–13 In order 
to address these issues, extensive combinatorial biosynthesis has been performed on the 
MTM pathway and has resulted in several novel analogs.14–16 The present authors have 
shown that the inactivation of the mtmW gene, which codes for the last enzyme in the 
MTM biosynthetic pathway, yields the most favorable of the new analogs, MTM SK 
(SK) and MTMSDK (SDK).15,16 Both SK and SDK exhibited higher anticancer activity 
than the native MTM,15,16 yet their short plasma retention time and low accumulation 
in tumors remained to be improved.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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A drug-delivery system is a technique that ensures 
drug molecules are delivered to disease lesions at the right 
amount and timing by using drug carriers. Nanoparticles 
are widely used as drug carriers because large molecules 
(.50 kDa) can avoid renal clearance and circulate in the 
body for prolonged time in comparison to small molecules.17 
Tumors are characterized with leaky blood vessels and 
immature   lymphatic drainage, which allow nanoparticles 
(20–200 nm) to accumulate in tumor tissues.18 Nanoparticles 
take advantage of both prolonged plasma retention time and 
preferential tumor accumulation to deliver drug payloads to 
tumors preferentially.19 Liposomes, dendrimers, and polymer 
micelles are nanoparticulate formulations used widely for 
tumor-preferential delivery of therapeutic agents. Among 
these formulations, polymer micelles offer a versatile plat-
form that can be prepared through self-assembling of block 
copolymers in aqueous solutions.20 Self-assembled polymer 
micelles possess a core compartment enveloped by a hydro-
philic shell. The core-shell structure protects drug payloads 
from precipitation, protein adsorption, and enzymatic deg-
radation in the body. The polymer micelles can dissociate 
as the core becomes unstable under conditions accompanied 
by dilution, drug release, or polymer degradation.21 Polymer 
micelles can be stabilized by cross-linking in the core or 
shell to avoid premature micelle dissociation during tumor-
preferential drug delivery.22,23
In addition to tumor-preferential drug delivery, controlled 
drug release is another important factor for nanoparticles 
to maximize therapeutic efficacy of drug payloads. Drug 
binding linkers are normally designed to degrade in 
response to pH, enzymatic activity, light, or heat.24 The 
hydrazone bond, involved in many biomolecular events, 
is stable at physiological Ph (7.4), yet is cleaved in acidic 
conditions (pH , 7.0) in a pH-dependent manner. Such a 
unique degradation pattern has been employed to design 
pH-controlled drug-delivery systems that can trigger drug 
release in intracellular lysosomal compartments (pH 5.0), 
following the cellular uptake of drug carriers.25 Tumor tissues 
are also acidic (pH 6.5–7.0) due to the inefficient glucose 
consumption that massively produces lactic acids.26 Low pH 
in tumors is also attributed to high flux at the glyceraldehydes-
3-phosphate dehydrogenase step of glycolysis.27 These two 
factors contribute to tumor acidosis in combination. The 
authors of this paper previously demonstrated that polymer 
micelles to which drug molecules were conjugated through 
acid-sensitive hydrazone linkers could accelerate drug release 
in cancer cells and reduce systemic toxicity in animal tumor 
models.28 The hydrazone is a chemical bond between ketone 
and hydrazide groups, and thus, drug molecules containing 
ketone groups are advantageous to design pH-sensitive drug-
delivery systems.29–31
Figure 1 shows the likely chemical structures of MTM 
analogs (SK and SDK) and two nanoparticulate formula-
tions (self-assembled and cross-linked polymer micelles) 
used in this study. SK and SDK possess one and two ketone 
groups, respectively, in their 3-side chains, plus an additional 
keto group in the tricyclic ring system. At least one of the 
ketone groups is subsequently bound to hydrazide groups of 
poly(ethylene glycol)-poly(aspartate hydrazide) [PEG-p(Asp-
Hyd)] block copolymers to prepare drug-conjugated polymer 
micelles. The acid-labile hydrazone bonds between the block 
copolymers and MTM analogs are used to accelerate drug 
release in acidic conditions corresponding to tumor tissues 
in vivo. Self-assembled and cross-linked micelles are com-
pared to investigate the influence of micelle stability on drug-
release patterns. A549 cell lines (human nonsmall cell lung 
cancer) are used to test biological activity of nanoparticulate 
MTM formulations. This article, therefore, provides an 
insight and understanding of the design, development, and 
properties of MTM nanoparticulate formulations for effec-
tive cancer therapy.
Materials and methods
Materials
L-aspartic acid β-benzyl ester (BLA), triphosgene, anhy-
drous hydrazine, N,N′-diisopropylcarbodiimide (DIC), 
N-hydroxysuccinimide (NHS), anhydrous tetrahydrofuran 
(THF), anhydrous hexane, anhydrous ethyl ether, anhydrous 
dimethyl sulfoxide (DMSO), DMSO (molecular biology 
grade, $99.9%), DMSO-d6, resazurin sodium salt, acetate 
buffer solution, phosphate buffer solution, adipic acid, and 
sodium hydroxide (NaOH) were purchased from Sigma-
Aldrich (St Louis, MO). α-Methoxy-ω-amino PEG (5 kDa) 
was purchased from NOF Corporation (Tokyo, Japan). 
Regenerated cellulose dialysis bags with molecular weight 
cutoff (MWCO) 6–8 kDa and Slide-A-Lyzer G2 dialysis cas-
settes with MWCO 10 kDa, methanol (MeOH), acetonitrile 
(ACN), celite, C18 RP silica gel, tryptic soy broth (TSB), 
LB broth, Difco™ agar, sucrose, potassium sulfate, mag-
nesium chloride, glucose, casamino acids, yeast extract, 
MOPS (3-morpholinopropane-1-sulfonic acid), and trace 
elements were purchased from Fisher Scientific (Ottawa, 
ON). Streptomyces argillaceus ATCC 12956 was purchased 
from ATCC (Manassas, VA). Spectra/Por 6 dialysis tubing 
with MWCO 50 kDa was purchased from Spectrum Labs 
(Fort Lauderdale, FL).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Biosynthesis of MTM analogs
SK and SDK were produced by an adapted procedure 
reported previously.15 Cells of S. argillaceus M7W1 were 
plated on R5A agar and grown for 4 days. After 4 days, the 
spores were used to inoculate 100 mL of TSB for 24 hours 
in an orbital shaker at 28°C, 250 rpm. After 24 hours, 4 mL 
of the TSB culture was used to inoculate 40, 100 mL flasks 
of R5A media. The cultures were grown for 3 days at 28°C, 
250 rpm. After 3 days the cells were harvested and 50 g/L 
celite was added to the culture. The cells were removed by 
filtration, re-dissolved in MeOH and sonicated for 1 hour to 
lyse the cells. After sonication the cells were filtered again 
and the MeOH was removed from the filtrate, reconstituted 
in water, and loaded onto a 5 cm × 12 cm C18 RP column 
equilibrated with 10 column volumes of water. The column 
was washed with 10% ACN in water, followed by 20% ACN 
in water, and subsequently eluted with 100% ACN. The 
filtrate from the initial removal of the cells was also loaded 
onto the C18 column, followed by the same fractionation 
procedure. The samples were dried and re-dissolved in 80% 
MeOH and water. The compounds were further isolated by 
semi-preparative high-performance liquid chromatography 
(HPLC).
Block copolymer synthesis
Block copolymers were synthesized as reported previously 
(Figure 2).22 In brief, BLA-N-carboxy anhydride (BLA-NCA) 
was prepared as a monomer by adding 2.88 g of triphosgene 
to 5.0 g β-benzyl-L-aspartate in 100 mL of dry THF at 45°C 
until the solution became clear. Anhydrous hexane was added 
to the solution slowly to form BLA-NCA crystal, which was 
recrystallized at −20°C. PEG was used as a macroinitiator 
to conduct the ring-opening polymerization of BLA-NCA, 
which produced PEG-(β-benzyl L-aspartate) [PEG-PBLA]. 
BLA-NCA and PEG were reacted in anhydrous DMSO at 
50 mg/mL under N2 for 2 days at 45°C. The PEG-PBLA 
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Figure 1 Self-assembled and cross-linked polymer micelles as nanoparticulate formulations for MTM analogs.
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block copolymers were isolated from the reaction mixture 
by precipitation with anhydrous ethyl ether and subsequently 
freeze drying. PEG-PBLA (100 mg/mL) was reacted with 
20-fold equivalent hydrazine in DMSO (40°C) for 1 hour to 
prepare PEG-p(Asp-Hyd) block copolymers. The   materials 
were collected by ether precipitation and freeze drying. 
The block copolymer compositions were determined by 
  proton nuclear magnetic resonance spectroscopy (1H-NMR), 
which is described as X-Y denoting the molecular weight 
of PEG × 10−3 (X) and the number of aspartate repeating 
units (Y), respectively.
Synthesis of self-assembled polymer 
micelles
MTM analogs were conjugated to the PEG-p(Asp-Hyd) 
block copolymers by adding both SK and SDK to the block 
copolymer at 50 weight % in DMSO. The reaction was 
allowed to proceed at room temperature for 72 hours,   shaking 
at 500 rpm. The materials were collected and purified by 
repeating ether precipitation. The drug-polymer conjugates 
were then re-dissolved in deionized water to form self-
assembled micelles. The drug-loaded micelles were collected 
by freeze drying.
Synthesis of cross-linked polymer 
micelles
Cross-linked polymer micelles were created by cross-linking 
PEG-p(Asp-Hyd) 5–40 with adipic acid. PEG-p(Asp-Hyd) 
5–40 was dissolved in DMSO to a final concentration of 
100 mg/mL. Adipic acid, NHS, and DIC were combined in 
DMSO to a mole ratio of 0.5:4:4 times the hydrazide groups 
of the block copolymer, respectively, and the reaction mixture 
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was added to the block copolymer. The cross-linking reaction 
was conducted for 72 hours, stirring at room temperature. 
The reaction solution was then dialyzed against DMSO, 
followed by 50% DMSO, and finally deionized water. The 
solution was freeze dried to collect the purified materials. The 
cross-linked micelles were characterized by gel permeation 
chromatography (GPC) and 1H-NMR. MTM analogs were 
conjugated to cross-linked micelles at a 50 weight % in 
DMSO, followed by ether precipitation and freeze drying.
Micelle characterization
Drug loading efficiency in polymer micelles was determined 
by quantifying the absorbance of MTM analogs at 410 nm. 
Particle size of the micelles was determined by dynamic 
light scattering (DLS) on a Zetasizer Nano-ZS (Malvern 
Instruments Ltd, Worcestershire, UK) equipped with a He-Ne 
laser light source and 173° angle scattered light collection 
configuration.
Drug-release experiments
Drug-release patterns of the self-assembled or cross-linked 
polymer micelles were evaluated by using dialysis cassettes 
(Slide-A-Lyzer G2, MWCO 10 kDa). Dialysis cassettes 
containing 2 mL samples were placed in 4 L of phosphate 
buffer solution (10 mM, pH 7.4 or 5.0). The temperature was 
maintained at 37°C. An aliquot of 150 µL was taken out of 
each dialysis cassette at the time intervals of 0.0, 0.5, 1.0, 
3.0, 6.0, 24.0, 48.0, and 72.0 hours. The aliquots taken at 
each time point were analyzed by ultraviolet-visible (UV-Vis) 
absorbance at 410 nm. All experiments were performed in 
triplicate.
cell toxicity assays
The cytotoxic effects of four MTM nanoparticulate for-
mulations were investigated in comparison to free drugs. 
A549 cells were cultured as specified from ATCC at 37°C, 
5% CO2. The cells were seeded on a 96-well plate (5000 cells/
well) and allowed to adhere for 24 hours. After 24 hours, 
growth media were replaced with fresh media containing 
samples at differing concentrations. 1% DMSO (biotech-
nological grade) was used as a control vehicle to prepare 
free drug formulations for SK and SDK. Self-assembled 
and cross-linked micelles were used as nanoparticulate 
formulations for SK and SDK. The cells were exposed to 
samples for 72 hours total (n = 8). Cell viability was assessed 
using a resazurin assay that indicates mitochondrial meta-
bolic activity in live cells. A volume of 10 µL of a 1 mM 
resazurin solution in phosphate buffered saline was added to 
the vehicle- and drug-treated cells at the end of the treatment 
period. Cell viability was determined 3 hours later by reading 
the fluorescence at 560 nm (excitation wavelength)/590 nm 
(emission wavelength). The fluorescence signals were 
quantified using a Spectramax M5 plate reader (Molecular 
Devices, Sunnyvale, CA) equipped with SoftMax® Pro 
(Molecular Devices) software. Cytotoxicity was determined 
by calculating the half maximal inhibitory concentration 
(IC50) of each sample.
Results
Biosynthesis of SK and SDK
SK and SDK were successfully produced by the S.   argillaceus 
M7W1, and isolated through an adapted procedure   developed 
previously.15 S. argillaceus cells of the M7W1 mutant strain 
were plated on R5A agar and allowed to grow until spores 
were formed. After 2 days, colonies began to appear on the 
plates; after 3 days, spores began to form; and after 4 days, 
the majority of the cells were present as spores. Spores from 
the plate were used to inoculate an initial culture of TSB 
media. The cells grew quickly in TSB media and were ready 
to transfer to R5A media after 24 hours. Once transferred to 
the R5A growth media, the cells were able to produce the 
drug analogs. Initially the media was adjusted to pH 6.85; 
however, after the observation of the production, the pH was 
adjusted to 7.0. The culture was monitored for the emergence 
of the MTM analogs using HPLC. After 24 hours, the pres-
ence of MTM analogs or precursors was not readily detected. 
After 48 hours, the MTM analogs began to appear; however, 
a large population of pre-MTM compounds was still observed. 
After 72 hours, the MTM compounds were the dominant 
compounds in the culture so the production was stopped. 
Much of the population of the MTM analogs was excreted 
in the culture media, thus the initial step of the isolation was 
to separate out the cells from the media by the addition of a 
celite cell-binding resin and subsequent filtration. Once the 
cells had been removed, the filtrate was passed over a C18 
RP silica gel column to collect the compounds of interest. 
The initial washes of 10% and 20% ACN allowed many 
of the byproducts to be removed from the sample. Further 
fractionation of the culture on the C18 RP column did not aid 
in the purification of the individual MTM analogs, so it was 
decided to elute all the MTM compounds together to mini-
mize sample loss and excessive dilution. The cells removed 
in the initial filtration step did still contain a substantial 
amount of SK and SDK, thus to take full advantage of the 
production of the analogs the cultured cells were covered in 
MeOH and sonicated to lyse the cells and release the drugs. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Cellular debris was removed by again filtering the solution 
which was then able to be dried, reconstituted in water, and 
loaded on the C18 RP column. After the same wash and 
elution steps were performed, a similar solution to the initial 
cell filtrate was obtained; however, in a smaller quantity. 
The samples could then be loaded and the individual MTM 
analogs separated by using semi-preparative HPLC. The 
individual peaks were collected and analyzed for purity using 
HPLC-mass spectrometry. Both the SK and SDK products 
were collected at .95% purity through this procedure and 
were stored at −20°C for future use.
Synthesis of polymer micelles
1H-NMR showed that PEG-p(Asp-Hyd) was successfully 
synthesized as reported previously22 and used to prepare 
self-assembled micelles. For cross-linked micelles, the 
cross-linking of PEG-p(Asp-Hyd) was confirmed by GPC. 
The cross-linked micelles had an average molecular weight 
of ∼147 kDa, corresponding to an average of roughly 14 block 
copolymers per cross-linked micelle. NMR was also used to 
determine the cross-linking percentage. The carboxyl peak 
of adipic acid at around 12 ppm disappeared, indicating that 
no unreacted or partially reacted adipic acid was present in 
the sample. The cross-linking percentage was 12.5%, which 
was determined by integrating the newly appeared peaks at 
2.1 ppm and 1.5 ppm (α and β CH2 groups of adipic acid) 
with respect to the PEG peak at 3.5 ppm.
characterization of MTM-loaded micelles
Following the drug conjugation reaction, ether precipitation 
was used to collect the polymers. Initial precipitations 
possessed a yellow supernatant corresponding to free drug that 
was not entrapped in the micelle structures. Ether precipitations 
were continued until the supernatant remained clear 
for several precipitations. The polymers maintained a 
yellowish color, after free drugs were removed, indicating 
the presence of the MTM analogs. UV-Vis absorption 
spectrometry at 410 nm confirmed that both SK and SDK 
were successfully entrapped in both the self-assembled 
micelles and cross-linked micelles. Drug loading in the self-
assembled micelles was 35.4 ± 0.3 and 44.6 ± 2.2 weight % 
(wt %) for SK and SDK, respectively. Cross-linked micelles 
had an average drug loading of 31.3 ± 0.3 and 42.7 ± 5.3 
wt % for SK and SDK, respectively. DLS showed that the 
particle size of self-assembled micelles entrapping SK and 
SDK was 8.36 ± 3.21 and 12.19 ± 2.77 nm. The particle size 
of cross-linked micelles was 29.56 ± 4.67 nm for SK and 
30.48 ± 7.00 nm for SDK (Figure 3).
Drug-release experiments
A pH sensitive hydrazone linkage was used to conjugate 
MTM analogs to the block copolymers to take advantage of 
the acidic tumor environment. To test pH-responsive drug-
release patterns, MTM nanoparticulate formulations were 
incubated at pH 7.4 and 5.0. Figure 4 shows that all MTM 
nanoparticulate formulations released drugs effectively. At 
pH 7.4, self-assembled micelles entrapped more than 50% 
of MTM analogs for 24 hours, which will be stable enough 
to deliver drugs to tumor tissues following intravenous 
injections. Drug release from the self-assembled micelles 
was accelerated at pH 5.0, suggesting that SK and SDK will 
be released effectively in acidic tumor tissues. Cross-linked 
micelles appeared to release drugs more quickly at pH 7.4 
than self-assembled micelles, yet retained 40% of drugs for 
24 hours. Both SK and SDK were released more rapidly from 
cross-linked micelles at pH 5.0.
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cell toxicity assays
Cytotoxicity of MTM nanoparticulate formulations was 
tested with A549 cells (Figure 5). Free SK and SDK showed 
IC50   values of 0.163 ± 0.092 µM and 0.093 ± 0.035 µM, 
respectively. IC50 values of self-assembled micelles 
entrapping MTM analogs were 0.262 ± 0.087 µM and 
0.282 ± 0.131 µM for SK and SDK, which were 1.6- and 
3.0-fold higher than those of free drugs. Interestingly, cross-
linked micelles showed IC50 values of 0.073 ± 0.015 µM and 
0.075 ± 0.009 µM for SK and SDK, which were 2.2- and 
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1.2-fold lower than free drugs (Table 1). No toxicity was 
observed with block copolymers, self-assembled micelles 
and cross-linked micelles alone up to 100 µM (data not 
shown).
Discussion
As mentioned above, MTM has been limited clinically by 
the severe negative side effects associated with the use of 
the drug. However, MTM has shown promise with respect 
to treating neurological diseases, glioblastomas, and other International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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tumors in addition to showing the ability to inhibit the 
multidrug resistance gene, MDR1, in which smaller, less 
toxic doses are required.32–37 Recently, MTM was identified 
as the lead compound against the Friend leukemia virus 
integration 1 (EWS-FLI1) transcription factor.38 EWS-FLI1 
is believed to be responsible for malignant transformation 
and progression of Ewing sarcoma family tumors and was 
widely regarded as undruggable because it is a transcrip-
tion factor.38 A high-throughput screening of over 50,000 
  compounds identified MTM as the top candidate from the 
screen and greatly reduced and inhibited tumor volume in 
Ewing sarcoma family tumors in mouse xenograft models, 
and it is planned to reinstitute clinical trials for this applica-
tion of MTM.38 Additionally, a combinational approach of 
MTM with betulinic acid to treat pancreatic cancer showed 
the ability to synergistically treat the cancer with a nontoxic 
dose of the drugs to produce less discernible side effects.35 As 
new treatments and uses for MTM continue to be uncovered, 
the development and optimization of a compatible drug-
delivery system will be necessary.
The potential of MTM has been enhanced by the dis-
covery of two new analogs produced through engineering 
of the MTM biosynthetic pathway. These analogs, SK and 
SDK, are a result of the inactivation of the mtmW gene and 
have shown improved activity compared with that of the 
native MTM. The biosynthesis and isolation of the SK and 
SDK analogs are pivotal as larger quantities of the drug 
will be required for testing and eventually clinical use. SK 
and SDK are produced alongside two other compounds, a 
demycarosyl-MTM SK and MTM SA (SA). The SA analog 
shows decreased anticancer activity and the demycarosyl-
MTM SK shows activity similar to that of the native MTM, 
thus neither are the preferred products of the mutant strain. 
Initially, a culture pH of 6.85 was used for the production 
of the drugs. These conditions allowed for good production 
of the SK, but a large amount of SA and very little SDK 
were also being observed. The formation of SK, SDK, and 
SA are a result of the spontaneous rearrangement of the 
immediate product MTM DK, resulting from the MtmOIV 
reaction of the biosynthetic pathway.15,16 It has been shown 
by in-vitro work that the major product of the conversion of 
premithramycin B by MtmOIV can be shifted to SDK at a 
pH of 8.25.39 In an effort to improve the production of SDK 
from the culture, the pH of the media was adjusted to 7.0. 
It was hoped that the adjustment of the pH, although small, 
would still allow optimal growth of the M7W1 mutant strain 
and production of the MTM analogs, but that the production 
yield of SDK would be improved. Increasing the pH of the 
growth media to 7.0 confirmed the hypothesis and increased 
the production yield of SDK. Increasing the pH also did not 
appear to adversely affect the production of SK. This will be 
critical as the production of the analogs is scaled up to meet 
the clinical demands.
As the drive for more specific and efficient chemothera-
peutic options continues, delivery systems will undoubtedly 
play a pivotal role in their development and advancement. To 
that end, these novel MTM formulations still need to resolve 
issues such as low tumor accumulation, poor bioavailabil-
ity, and short plasma retention time to be further explored 
clinically. Drug-delivery systems are expected to address 
these concerns by delivering MTM preferentially to tumors. 
Liposomal formulations have been previously tested, but the 
release of MTM analogs from liposomes has proved to be 
difficult.40 Studies suggest that polymer micelles will offer 
an alternative platform for the delivery of MTM, not only 
delivering the drug to tumors but also controlling the drug-
release patterns efficiently. It has been demonstrated that 
block copolymers offer a versatile platform in this direction. 
In this study, MTM analogs (SK and SDK) were entrapped 
in polymer micelles through an acid-labile hydrazone con-
jugation between drug molecules and micelle-forming block 
copolymers. Prepared MTM nanoparticulate formulations 
appeared to combine the favorable characteristics of drug-
delivery systems with the ability to entrap drugs at high 
yields and to control the drug release at the area of interest.
SK and SDK have one and two ketone groups on the 
side chain. These ketone groups offer a prime location for 
the conjugation of the drugs to the PEG-p(Asp-Hyd) block 
Table 1 A summary of the characteristics and activity of the drug-loaded polymer nanoparticles and that of the free drugs for 
comparison
Drug 
formulation
SK SDK
Free Self-assembled  
micelles
Cross-linked  
micelles
Free Self-assembled  
micelles
Cross-linked 
micelles
Ic50 (nM) 163 ± 92 262 ± 87 73 ± 15 93 ± 36 282 ± 131 75 ± 9
Relative efficacy to free drug 1.00 0.62 2.23 1.00 0.33 1.24
Abbreviations: SDK, mithramycin SDK; SK, mithramycin SK.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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copolymers through the hydrazone bond. Self-assembled 
micelles showed higher drug loading of SDK (44.6 wt %) 
than SK (35.4 wt %), suggesting that the second ketone group 
of the SDK side chain could facilitate drug loading rather than 
saturating the drug-binding sites. The particle size of self-
assembled micelles was 44% larger with SDK (12.19 nm) 
than SK (8.36 nm), which is consistent with the increased 
SDK loading in micelles. The average particle size of cross-
linked micelles was 26.79 nm in the absence of drugs. Cross-
linked micelles were 29.56 and 30.48 nm after entrapping 
SK and SDK, respectively. Even though the particle size was 
retained, cross-linked micelles entrapped 31.3 wt % SK and 
42.7 wt % SDK, which were comparable to the amount of 
drugs that self-assembled micelles entrapped.
Again, an acid labile hydrazone bond was used to 
conjugate the drugs to the block copolymers so the release 
of the drugs from the nanoformulations was investigated 
at both the physiological pH of 7.4 and an intracellular 
endosome or lysosome pH of 5.0. Effective drug release 
was observed in all MTM nanoparticulate formulations 
tested improving on previous attempts of MTM delivery 
with liposomes. MTM analogs were released slowly from 
polymer micelles at pH 7.4 regardless of formulations. The 
drug release was accelerated at pH 5.0 (Figure 4), which 
is advantageous to release drugs in acidic tumor tissues. 
After 72 hours, however, the amount of drugs released was 
similar at both pH values. MTM nanoparticulate formula-
tions are expected to minimize drug leakage in the blood 
and maximize therapeutic efficacy by releasing drugs in 
tumor tissues rapidly.
MTM nanoparticulate formulations were shown to be 
effective to suppress cancer cell growth, indicating that 
MTM analogs were delivered in a biologically active form. 
Self-assembled micelles entrapping MTM analogs showed 
lower cytotoxic effects than free drugs as expected, but 
interestingly, cross-linked micelles enhanced drug efficacy 
up to 2.2-fold (Table 1). Although further investigation is 
necessary to elucidate the mechanism behind this intrigu-
ing phenomenon, the results of this study suggest that drug 
release in the early stage would not play a crucial role in 
determining cellular response to MTM analogs as all nano-
particulate formulations released a similar amount of drugs 
between 1 and 3 hours. Drug release at pH 7.4 rather than 5.0 
appeared to be the major factor that determines cytotoxicity. 
MTM analogs were effective to suppress cancer cell growth 
in order of cross-linked SK micelles, cross-linked SDK 
micelles, self-assembled SK micelles, and self-assembled 
SDK micelles, which is consistent with the drug-release 
patterns at pH 7.4, whereas all nanoparticulate formulations 
released drugs similarly at pH 5.0, which does not explain 
differential cytotoxicity observed in A549. Therefore, it is 
more reasonable to assume that drugs released from micelles 
at pH 7.4 comprise the major drug population that involved 
in cell killing, while intracellular drug release (pH 5.0) has 
less effect on overall cytotoxicity of MTM nanoparticulate 
formulations. However, detailed intracellular mechanisms 
on how cells respond to MTM nanoparticulate formulations 
(eg, particle size and intracellular drug distribution) should 
be investigated further in the future.
Cross-linked micelles had a 12.5% cross-linking yield, 
which was high enough to tether block copolymer chains 
before and after entrapping drugs without causing agglom-
eration between particles. In spite of the high cross-linking 
yield, cross-linked micelles entrapped and released MTM 
analogs effectively. Importantly cross-linked micelles 
released drugs more quickly than self-assembled micelles, 
implicating that MTM analogs could be entrapped in the 
vicinity rather than at the center of the micelle core. The 
rapid drug release from cross-linked micelles can be also 
attributed to the rigid environment in the cross-linked core 
of the micelles. Cross-linking the core could allow for a 
more porous and less tightly packed core in the micelles so 
that drug molecules can maneuver more easily out of the 
core. In contrast, self-assembled micelles have a flexible 
core that can continue to pull block copolymers to keep the 
particle stable as drugs are released. This may explain why 
drug release from self-assembled micelles was slower than 
cross-linked micelles.
Cytotoxic effects of MTM nanoparticulate formulations 
revealed an interesting phenomenon that can be used to 
design potent drug-delivery systems. Unlike self-assembled 
micelles that decreased the toxicity of MTM analogs, cross-
linked micelles showed a higher potency against A549 cancer 
cells than free drugs. The exact mechanism and reason for 
the improved efficacy is yet to be confirmed, although the 
more stable cross-linked micelles could aid in the drug’s 
persistence in the cells, allowing more drugs to interact with 
the therapeutic targets in the cell. In addition to the known 
mechanism of the MTM family of compounds in which they 
bind the GC rich DNA present in Sp family of promoters, the 
expression of the gene encoding for a multidrug resistance 
efflux pump, MDR1, has also been shown to be inhibited by 
MTM and some of it derivatives.36,37 This would make the 
MTM nanoparticulate formulations excellent candidates for 
combinational therapy attacking hard-to-treat, multidrug-
resistant cancer cell lines. Future studies will explore International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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whether these results translate in vivo and dig deeper into 
the reasoning behind the improved activity.
Conclusion
Nanoparticulate formulations for controlled delivery of MTM 
analogs, SK and SDK, were prepared by using self-assembled 
or cross-linked polymer micelles from PEG-p(Asp-Hyd) 
block copolymers to which drugs were conjugated through 
acid-labile hydrazone bonds. With recent interest in MTM 
for several novel treatment approaches, a compatible delivery 
system with ability to selectively deliver the drug to the area 
of interest would be advantageous. Both the SK and SDK 
analogs offer higher anticancer activity compared with MTM 
and thus were investigated with respect to a compatible 
delivery system. SK and SDK were successfully loaded into 
polymer micelles and demonstrated a pH-dependent release 
profile, accelerating drug release at pH 5.0. By cross-linking 
the micelles, the size of the particles was increased without 
significantly affecting the drug loading. Both the self-
assembled and cross-linked structures were able to deliver the 
drugs in the biologically active form and efficiently kill the 
human nonsmall cell lung cancer cell line (A549). The cross-
linked micelles interestingly improved the cytotoxicity of 
MTM analogs, even compared with the free drugs. The ability 
to prepare delivery platforms without losing any biological 
activity will streamline the development of therapeutic 
options, and these results conclude that nanoparticulate 
formulations offer prime candidates to pave the path for SK, 
SDK, and other MTM analogs to be explored further with 
animal models and potentially in the clinical field.
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